

AUSTRIA

Recent and planned developments in pharmaceutical policies 2015

Pre-launch activities: horizon scanning and forecasting

| | | |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D E V E L O P M E N T S | Changes in pricing | Changes in reimbursement |
| | <ul style="list-style-type: none"> • <u>No changes</u> | <ul style="list-style-type: none"> • <u>Annual adjustment of the prescription fee:</u> Prescription fee of 5.55 € in 2015 • <u>Increase in application fees:</u> In 2014, the application fees for the inclusion into the Reimbursement Code were increased for the first time in five years (by 5.0%). In 2015 the fees rose again by 2.5%. |
| | Other changes | |
| | <ul style="list-style-type: none"> • <u>New appeal institution started to work:</u> The first two public hearings of the Federal Administrative Court took place in November 2014 and January 2015. • <u>Outlook:</u> The framework agreement between the Main Association of Social Insurance Institutions and pharmaceutical industry that was concluded in 2008 and prolonged in mid-2011 will end in December 2015. | |
| S P E C I A L T O P I C | Pre-launch pharmaceutical policies: Horizon Scanning and Forecasts | |
| | <p>In 2007, the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) was commissioned by regional hospital co-operations and the Ministry of Health to set up a Horizon Scanning System in Oncology (background: Austria has a high rate of adoption of new oncology medicines).</p> <p>Aim of the project: To facilitate the evidence-based use of anti-cancer therapies and to pre-estimate their potential financial implications in order to better inform decision-makers before the routine introduction of anti-cancer therapies into clinical practice.</p> <p>Since then, assessments of new oncology medicines have been regularly published.</p> | |